{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:17:04Z","timestamp":1750306624394,"version":"3.41.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Canc Educ"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s13187-024-02524-8","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T07:03:20Z","timestamp":1729321400000},"page":"408-415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Survey on Knowledge and Attitudes Towards Vaccination Against Herpes Zoster Virus Among Medical Oncologists for Patients with Solid Tumors"],"prefix":"10.1007","volume":"40","author":[{"given":"Giuseppa","family":"Scandurra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Sambataro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8406-9416","authenticated-orcid":false,"given":"Vittorio","family":"Gebbia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Rosaria","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,19]]},"reference":[{"issue":"5.5","key":"2524_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.6004\/jnccn.2022.5014","volume":"20","author":"MA Rodriguez","year":"2022","unstructured":"Rodriguez MA (2022) Vaccinations for Patients with Cancer and Cancer Survivors. J Natl Compr Cancer Netw 20(5.5):607\u2013610","journal-title":"J Natl Compr Cancer Netw"},{"key":"2524_CR2","doi-asserted-by":"publisher","unstructured":"Sanft T, Day A, Ansbaugh S, Armenian S, Baker KS, Ballinger T, Demark-Wahnefried W, Dickinson K, Fairman NP, Felciano J, Flores TF, Friedman DL, Gabel NM, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Koura D, Lee K, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, Neuman H, O'Connor T, Overholser L, Paskett ED, Patel C, Peterson L, Pirl W, Porpiglia A, Rodriguez MA, Schapira L, Schwartz AL, Smith S, Tevaarwerk A, Yang E, Zee P, McMillian NR, Freedman-Cass DA (2023) NCCN Guidelines\u00ae Insights: Survivorship, Version 1.2023. J Natl Compr Canc Netw 21(8):792\u2013803. https:\/\/doi.org\/10.6004\/jnccn.2023.0041","DOI":"10.6004\/jnccn.2023.0041"},{"issue":"1","key":"2524_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40257-019-00483-1","volume":"21","author":"LL Rosamilia","year":"2020","unstructured":"Rosamilia LL (2020) Herpes Zoster Presentation, Management, and Prevention: A Modern Case-Based Review. Am J Clin Dermatol 21(1):97\u2013107. https:\/\/doi.org\/10.1007\/s40257-019-00483-1","journal-title":"Am J Clin Dermatol"},{"key":"2524_CR4","doi-asserted-by":"publisher","unstructured":"Pedrazzoli P, Lasagna A, Cassaniti I, Ferrari A, Bergami F, Silvestris N, Sapuppo E, Di Maio M, Cinieri S, Baldanti F (2022) Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM). ESMO Open 7(4):100548. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100548.","DOI":"10.1016\/j.esmoop.2022.100548"},{"issue":"2","key":"2524_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s15010-013-0550-8","volume":"42","author":"SY Chen","year":"2014","unstructured":"Chen SY, Suaya JA, Li Q, Galindo CM, Misurski D, Burstin S, Levin MJ (2014) Incidence of herpes zoster in patients with altered immune function. Infection 42(2):325\u201334. https:\/\/doi.org\/10.1007\/s15010-013-0550-8","journal-title":"Infection"},{"issue":"6","key":"2524_CR6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s15010-011-0162-0","volume":"39","author":"A Hata","year":"2011","unstructured":"Hata A, Kuniyoshi M, Ohkusa Y (2011) Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection 39(6):537\u2013544. https:\/\/doi.org\/10.1007\/s15010-011-0162-0","journal-title":"Infection"},{"key":"2524_CR7","doi-asserted-by":"publisher","unstructured":"Sullivan KM, Farraye FA, Winthrop KL, Willer DO, Vink P, Tavares-Da-Silva F (2023) Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions. Vaccine 4;41(1):36\u201348. https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.063.","DOI":"10.1016\/j.vaccine.2022.10.063"},{"key":"2524_CR8","unstructured":"Harpaz R, Ortega-Sanchez IR, Seward JF (2008) Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 57(RR-5):1\u201330, quiz CE2\u20134."},{"issue":"22","key":"2524_CR9","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1056\/NEJMp058091","volume":"352","author":"A Arvin","year":"2005","unstructured":"Arvin A (2005) Aging, immunity, and the varicella-zoster virus. N Engl J Med 352(22):2266\u20132267. https:\/\/doi.org\/10.1056\/NEJMp058091","journal-title":"N Engl J Med"},{"issue":"12","key":"2524_CR10","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","volume":"213","author":"HF Tseng","year":"2016","unstructured":"Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, Bialek S, Hechter RC, Jacobsen SJ (2016) Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged \u226560 Years. J Infect Dis 213(12):1872\u20131875. https:\/\/doi.org\/10.1093\/infdis\/jiw047","journal-title":"J Infect Dis"},{"issue":"1","key":"2524_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/infdis\/jiy626","volume":"220","author":"K Kawai","year":"2019","unstructured":"Kawai K, Yawn BP (2019) Risk of Herpes Zoster in Cancer Patients and the Promise of New Vaccines. J Infect Dis 220(1):1\u20132. https:\/\/doi.org\/10.1093\/infdis\/jiy626","journal-title":"J Infect Dis"},{"issue":"6","key":"2524_CR12","doi-asserted-by":"publisher","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833.","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ (2014) Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 4(6):e004833. https:\/\/doi.org\/10.1136\/bmjopen-2014-004833.","journal-title":"BMJ Open"},{"key":"2524_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.puhe.2024.01.024","volume":"229","author":"F Lapi","year":"2024","unstructured":"Lapi F, Marconi E, Concia E, Parretti D, Murrone A, Rossi A, Perno CF, Cricelli C (2024) Time-varying association between herpes zoster infection and subsequent occurrence of stroke. Public Health 229:80\u201383. https:\/\/doi.org\/10.1016\/j.puhe.2024.01.024","journal-title":"Public Health"},{"issue":"3","key":"2524_CR14","doi-asserted-by":"publisher","first-page":"e1335","DOI":"10.1093\/cid\/ciac549","volume":"76","author":"GI Parameswaran","year":"2023","unstructured":"Parameswaran GI, Wattengel BA, Chua HC, Swiderek J, Fuchs T, Carter MT, Goode L, Doyle K, Mergenhagen KA (2023) Increased Stroke Risk Following Herpes Zoster Infection and Protection With Zoster Vaccine. Clin Infect Dis 76(3):e1335\u2013e1340. https:\/\/doi.org\/10.1093\/cid\/ciac549","journal-title":"Clin Infect Dis"},{"key":"2524_CR15","unstructured":"de la Serna J, Campora L, Chandrasekar P, El Idrissi M, Gaidano G, Lopez Fauqued M, Oostvogels L, Schwarts S, Sullivan KM, Szer J, Bastidas A (2018) Efficacy and safety of an adjuvanted herpes zoster subunit vaccine in autologous hematopoietic stem cell transplant recipients 18 years of age or older: first results of the phase 3 randomized, placebo\u2010controlled ZOE\u2010HSCT clinical trial [abstract# 11724]. Abstract presented at: BMT Tandem Meetings; February 25th, Salt Lake City, UT."},{"key":"2524_CR16","doi-asserted-by":"publisher","unstructured":"Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, L\u00f3pez-Jim\u00e9nez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, Gaidano G, Lee JJ, Abhyankar S, Solano C, Perez de Oteyza J, Satlin MJ, Schwartz S, Campins M, Rocci A, Vallejo Llamas C, Lee DG, Tan SM, Johnston AM, Grigg A, Boeckh MJ, Campora L, Lopez-Fauqued M, Heineman TC, Stadtmauer EA, Sullivan KM, ZOE-HSCT Study Group Collaborators (2019) Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. JAMA 322(2): 123\u2013133. https:\/\/doi.org\/10.1001\/jama.2019.9053. Erratum in: JAMA 322(8):785, 2019.","DOI":"10.1001\/jama.2019.9053"},{"key":"2524_CR17","doi-asserted-by":"publisher","unstructured":"Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barber\u00e0 J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC; ZOE-50 Study Group (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372(22):2087\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1501184.","DOI":"10.1056\/NEJMoa1501184"},{"issue":"11","key":"2524_CR18","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, D\u00edez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barber\u00e0 J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC (2016) ZOE-70 Study Group: Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med 375(11):1019\u20131032. https:\/\/doi.org\/10.1056\/NEJMoa1603800","journal-title":"N Engl J Med"},{"key":"2524_CR19","unstructured":"Istituto Superiore di Sanit\u00e0 www.epicentro.iss.it"},{"key":"2524_CR20","doi-asserted-by":"publisher","unstructured":"Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio-Viqueira B, Jung KH, Rodriguez Moreno JF, Grande E, Marrupe Gonzalez D, Lowndes S, Puente J, Kristeleit H, Farrugia D, McNeil SA, Campora L, Di Paolo E, El Idrissi M, Godeaux O, L\u00f3pez-Fauqued M, Salaun B, Heineman TC, Oostvogels L; Zoster-028 Study Group (2019) Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial. Cancer 125(8):1301\u20131312. https:\/\/doi.org\/10.1002\/cncr.31909.","DOI":"10.1002\/cncr.31909"},{"key":"2524_CR21","doi-asserted-by":"publisher","unstructured":"Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, Sohn SK, Rodriguez Mac\u00edas G, Chiou TJ, Quiel D, Aoun M, Navarro Matilla MB, de la Serna J, Milliken S, Murphy J, McNeil SA, Salaun B, Di Paolo E, Campora L, L\u00f3pez-Fauqued M, El Idrissi M, Schuind A, Heineman TC, Van den Steen P, Oostvogels L; Zoster-039 study group (2019) Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis 19(9):988\u20131000, https:\/\/doi.org\/10.1016\/S1473-3099(19)30163-X. Erratum in: Lancet Infect Dis 20(1): e1, 2020.","DOI":"10.1016\/S1473-3099(19)30163-X"},{"issue":"3","key":"2524_CR22","doi-asserted-by":"publisher","first-page":"2288282","DOI":"10.1080\/21645515.2023.2288282","volume":"19","author":"A Lasagna","year":"2023","unstructured":"Lasagna A, Mele D, Bergami F, Alaimo D, Dauccia C, Alessio N, Comolli G, Pasi F, Muzzi A, Novelli V, Baldanti F, Pedrazzoli P, Cassaniti I (2023) The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy. Hum Vaccin Immunother 19(3):2288282. https:\/\/doi.org\/10.1080\/21645515.2023.2288282","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"2524_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1177\/03008916231191547","volume":"110","author":"A Lasagna","year":"2024","unstructured":"Lasagna A, Brunello A, Silvestris N, Pedrazzoli P, Di Maio M, Cinieri S (2024) Italian oncologists and vaccinations against infectious diseases: Results of a survey of the Italian Association of Medical Oncology. Tumori 110(1):60\u201368. https:\/\/doi.org\/10.1177\/03008916231191547","journal-title":"Tumori"},{"key":"2524_CR24","doi-asserted-by":"publisher","unstructured":"L\u00f3pez-Fauqued M, Campora L, Delannois F, El Idrissi M, Oostvogels L, De Looze FJ, Diez-Domingo J, Heineman TC, Lal H, McElhaney JE, McNeil SA, Yeo W, Tavares-Da-Silva F; ZOE-50\/70 Study Group (2019) Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials. Vaccine 37(18):2482\u20132493. https:\/\/doi.org\/10.1016\/j.vaccine.2019.03.043","DOI":"10.1016\/j.vaccine.2019.03.043"},{"issue":"5","key":"2524_CR25","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1080\/21645515.2016.1265715","volume":"13","author":"O Godeaux","year":"2017","unstructured":"Godeaux O, Kovac M, Shu D, Grupping K, Campora L, Douha M, Heineman TC, Lal H (2017) Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults \u2265 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial. Hum Vaccin Immunother 13(5):1051\u20131058. https:\/\/doi.org\/10.1080\/21645515.2016.1265715","journal-title":"Hum Vaccin Immunother"},{"key":"2524_CR26","doi-asserted-by":"publisher","unstructured":"Strezova A, Diez-Domingo J, Al Shawafi K, Tinoco JC, Shi M, Pirrotta P, Mwakingwe-Omari A; Zoster-049 Study Group (2022) Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination. Open Forum Infect Dis 9(10):ofac485. https:\/\/doi.org\/10.1093\/ofid\/ofac485","DOI":"10.1093\/ofid\/ofac485"},{"issue":"2","key":"2524_CR27","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/j.ijid.2009.03.019","volume":"14","author":"F Cresswell","year":"2010","unstructured":"Cresswell F, Eadie J, Longley N, Macallan D (2010) Severe Guillain-Barr\u00e9 syndrome following primary infection with varicella zoster virus in an adult. Int J Infect Dis 14(2):e161\u2013e163. https:\/\/doi.org\/10.1016\/j.ijid.2009.03.019","journal-title":"Int J Infect Dis"},{"issue":"11","key":"2524_CR28","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1111\/jocd.14470","volume":"20","author":"JA Palanivel","year":"2021","unstructured":"Palanivel JA (2021) Herpes zoster after COVID-19 vaccination-Can the vaccine reactivate latent zoster virus? J Cosmet Dermatol 20(11):3376\u20133377. https:\/\/doi.org\/10.1111\/jocd.14470","journal-title":"J Cosmet Dermatol"}],"container-title":["Journal of Cancer Education"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13187-024-02524-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13187-024-02524-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13187-024-02524-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T06:45:24Z","timestamp":1750229124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13187-024-02524-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,19]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2524"],"URL":"https:\/\/doi.org\/10.1007\/s13187-024-02524-8","relation":{},"ISSN":["0885-8195","1543-0154"],"issn-type":[{"type":"print","value":"0885-8195"},{"type":"electronic","value":"1543-0154"}],"subject":[],"published":{"date-parts":[[2024,10,19]]},"assertion":[{"value":"13 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MRV, DS, and DP have no disclosures. GS and VG received GSK honoraria for participating in a scientific tumor board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}